Choosing the Right STR Profiling Partner: A Checklist for Biotech & Pharma

Data integrity underpins every R&D milestone. If a cell line is misidentified or cross-contaminated, entire datasets—and months of effort—can be called into question. Outsourcing short tandem repeat (STR) profiling is, therefore, not just "buying a test." It's selecting a strategic ally for your audit trail, publication readiness, and IP protection—strictly for research use only (RUO).

Disclosure: CD Genomics is our product. Mentions below are informational and non‑promotional.

How to use this checklist

Who should read what (practical checklist use by role):
- Procurement and legal: review NDAs, data transfer and retention clauses, change‑control language in contracts, and requested evidence (QMS summary, supplier onboarding steps). Look for contractual language that allows audit access to redacted QC artifacts and defines data ownership and deletion on project close‑out.
- QA/operations: verify the QMS artifacts (SOP index, change logs, CAPA records), run‑level QC practices, chain‑of‑custody ownership, and reproducibility evidence such as redacted maintenance logs, control run examples, and replicate policies.
- Scientists/analysts: inspect the typical data package (signed PDF report, allele table, electropherograms, machine‑readable tables), ask how ambiguous calls are resolved, and confirm database comparison outputs and interpretation notes are included.
What to request from each vendor (copy‑ready items for RFP or supplier questionnaire):
- Administrative and governance:
  - A one‑page QMS summary that lists controlled documents and the change‑control process.
  - A counter‑signed NDA template (redacted as needed) and a brief description of subcontractor controls.
- Deliverables and data package:
  - One redacted sample report (signed PDF) and an accompanying file list (CSV/XLSX of allele calls, raw electropherogram files or high‑res images, and any comparison outputs).
  - A short description of the allele‑calling workflow (software name/version in plain language and reviewer steps) and the format of database comparison outputs.
- Operational and technical policies:
  - Sample acceptance matrix (accepted sample types and basic QC thresholds in policy language) and chain‑of‑custody procedure (how samples are barcoded and tracked).
  - Replicate/re‑run policy and an example of when a re‑extraction or replicate PCR is triggered.
- Security and IP:
  - A 1–2 page security and data governance summary (encryption in transit/at rest, RBAC and audit logging, retention/deletion options).

If your internal lab prefers to keep STR profiling in‑house, use the same items above as a self‑audit: can your internal SOPs and records produce equivalent artifacts for audits, manuscripts, and grant requests? The make‑vs‑buy question should focus on whether internal investment in staff time, equipment maintenance, and procedural validation is justified compared with outsourcing to a partner that supplies auditable deliverables and independent verification.

Criterion 1 — Quality Assurance & Data Integrity (hero value)

The single most important differentiator is whether a provider operates with an industrial‑grade Quality Management System (QMS) and delivers auditable, publication‑ready outputs. Think of QMS as the scaffolding that keeps each run traceable, each exception documented, and each result reproducible.

1.1 QMS and documentation evidence

What to verify and request (expanded evidence list):

Documented SOP index and change‑control process: request the document index and a recent redacted change log entry showing why a method change occurred and how it was validated.
Instrument calibration and maintenance logs: ask for redacted examples showing scheduled calibration, a recorded out‑of‑tolerance event, and corrective steps taken to re‑qualify the system.
Internal audits and CAPA examples: request anonymized CAPA closure summaries demonstrating root‑cause analysis and preventive measures.
Personnel competency records: confirm there is a training matrix and periodic competency checks for analysts reviewing electropherograms.
Run‑level QC controls and acceptance criteria described in policy terms: request examples of positive and negative control traces and an allelic ladder run demonstrating sizing accuracy.

Why it matters: Journals, funders, and internal auditors expect traceable decision logs and reproducible deliverables; vendors that provide these artifacts reduce the administrative burden on your team when preparing manuscripts or audit packages.

Actionable checkpoint: Require a one‑page QMS summary and two to three redacted artifacts (change‑control entry, calibration log excerpt, and a CAPA closure summary) as a minimum evidence set for an initial vendor short‑list.

1.2 Publication‑ready deliverables (report anatomy)

Your report should be ready to support peer review and grant submissions without extra reformatting. A mature provider will deliver:

A signed PDF report describing method scope and a plain‑language interpretation (match, no‑match, novel, or mixture suspected).
An allele table by locus and any explanatory notes about loci that produced multiple peaks or off‑ladder calls.
High‑resolution electropherograms that let an independent reviewer evaluate peak shape, height, and stutter.
Machine‑readable exports (CSV/XLSX) of calls and QC metrics to support internal LIMS ingestion.
A human‑readable comparison statement showing database outputs and an interpretation rationale.

Example (anonymized): "Redacted Project A" — the vendor provided a signed report, allele table CSV, ABI/SCF raw traces, and a comparison statement that flagged a likely mixture; the vendor recommended replicate PCR and provided re‑extraction options. Such deliverables let the internal QA and PI document decisions and next steps without reprocessing raw data.

Actionable checkpoint: Demand a redacted sample report and an explicit file manifest listing exact file types you will receive.

1.3 Database interoperability and interpretation

A strong report explains how the profile was compared to reference repositories and how to interpret the result in operational terms.

What to verify and request:

Repository list used for comparison (e.g., ATCC, DSMZ, JCRB) and a short note describing whether the vendor provides the raw comparison output or a plain‑language summary.
Explanation of interpretation workflow: how similarity is summarized, what triggers follow‑up testing, and how mixtures or degraded profiles are called.
A sample comparison output (redacted) that shows the matched reference name and an accompanying interpretive note.

Why it matters: Public repositories publish reference STR profiles; asking for the comparison output and rationale enables your QA team to reproduce or challenge the interpretation if needed.

Actionable checkpoint: Request a comparison output and a one‑paragraph interpretive note about mixed or degraded samples.

Evaluation and comparison: a practical scoring approach (no numeric thresholds)

To make vendor comparisons operational, convert qualitative responses into a simple tally framework you can use during procurement reviews.

Create a short matrix with columns for: Evidence Provided (Yes/No), Artifact Quality (Acceptable / Needs Clarification), Transparency (High/Medium/Low), and Follow‑Up Required (Y/N).
Map key mandatory items (QMS summary, redacted sample report, security summary, submission guidelines) into the matrix as pass/fail gates. Recommended items (LIMS/API specs, extended database support, on‑site audit options) can be scored for priority.

Practical tip: Use the matrix to prioritize vendors that pass all mandatory gates and show high transparency on critical artifacts; schedule short follow‑up calls to resolve any "Needs Clarification" items before making a decision.

Post‑RFP review: evidence verification and panel composition

Once responses arrive, form a small cross‑functional review panel (suggested roles): Procurement lead, QA representative, a senior scientist with STR experience, and a legal/security reviewer. Assign each member 2–3 evidence items to verify and ask for supporting files where needed (e.g., raw electropherogram for an ambiguous call).

Suggested steps:

1. Triage responses against mandatory pass/fail items.

2. For shortlisted vendors, request live walkthroughs of the redacted report and a short demo of the secure delivery portal or transfer procedure.

3. Ask for references (anonymized project contacts or case summaries) that demonstrate handling of similar sample types or volumes.

4. Document the panel's decision rationale and retain redacted artifacts in procurement records for future audits.

Criterion 2 — Capacity & Operational Stability

A strong STR profiling service isn't just technically correct on a good day—it's operationally consistent across weeks, batches, analysts, and instruments. For biotech and pharma teams, this is what turns authentication into a dependable gate in your R&D workflow rather than a recurring fire drill.

2.1 Throughput you can plan around

Rather than asking for "fastest possible" processing, ask for evidence of predictable workflows under variable demand. A mature provider should be able to explain, in plain operational terms:

How work is queued, prioritized, and tracked (e.g., batching rules, run scheduling, sample accessioning cutoffs).
How they prevent bottlenecks when volumes fluctuate (e.g., parallel instruments, trained backup analysts, standardized run setup).
How exceptions are handled without losing traceability (e.g., documented re-runs, deviation records, consistent client communication).

Actionable checkpoint: Ask for a short, written description of the provider's scheduling and exception-handling process, plus an example of a redacted "issue-to-resolution" log (even a single anonymized case summary is helpful).

2.2 Sample acceptance scope and chain-of-custody

Operational stability starts before the first PCR step. Mislabeling, degraded input, or unclear packaging instructions can cause avoidable rework and ambiguous results.

What to verify and request:

Sample acceptance matrix in policy language (accepted sample forms such as gDNA and cell pellets; how the provider flags low-quality input; how they document "not testable" cases).
Chain-of-custody steps (barcoding, accessioning, and how sample IDs map to report IDs).
Packaging and submission instructions that reduce preventable failures.

If you need a practical reference point for onboarding expectations, you can align vendor instructions with your internal receiving SOP and require a consistent "submission checklist" for each shipment. For CD Genomics customers, the Sample Submission Guidelines can be used as an example of the level of specificity procurement and lab ops teams typically need.

Actionable checkpoint: Require a submission/receiving checklist (what labels must be present, what documentation must accompany samples, and what happens if information is missing).

2.3 Evidence of process consistency

For procurement reviews, "we're consistent" isn't a useful claim unless it's tied to artifacts. Without asking for proprietary metrics, you can still request auditable proof points:

Replicate and re-run policy (what triggers repeat testing; whether re-extraction is offered; how "borderline" calls are escalated for review).
Run-level controls policy (positive/negative controls, ladder runs) described at a policy level.
A description of how instrument performance is monitored over time (e.g., periodic calibration, maintenance, out-of-tolerance handling).

Actionable checkpoint: Ask for a redacted example showing how a borderline or ambiguous profile was handled—what was repeated, what was concluded, and how that decision was documented.

Criterion 3 — Data Security & Intellectual Property

STR profiling projects often involve proprietary cell lines, engineered models, or collaboration-sensitive programs. Even if STR data isn't "patient data," it can still be IP-relevant research information. Your vendor selection should treat security as part of data integrity.

3.1 Contractual and governance basics

Start with the governance layer. At minimum, procurement and legal should confirm:

NDA coverage and scope (including affiliates/subcontractors, if any).
Data ownership language (who owns raw files, processed tables, and reports).
Retention and deletion options at project close-out.
Access boundaries (who inside the provider can see your data; how access is approved and reviewed).

Actionable checkpoint: Request a short security and data governance summary that explicitly addresses ownership, retention/deletion, and subcontractor controls.

3.2 Secure transfer and controlled access

Ask how data moves and who can touch it—then ask for evidence.

What to verify and request:

Encryption in transit and at rest (described at a policy level).
Role-based access control (RBAC) and audit logs for downloads/access.
Secure delivery mechanism for the data package (portal vs. encrypted archive; how credentials are issued and revoked).

If your organization follows external guidance for responsible genomic data handling, it's reasonable to ask vendors to align to the same principles (confidentiality, access control, documented governance). NIH's Using Genomic Data Responsibly and Genomic Data User Code of Conduct are useful, general references for what "good governance" looks like in research contexts.

Actionable checkpoint: Require a written description of the delivery method and a statement of whether access events are logged and retrievable for audits.

Criterion 4 — Operational Efficiency: Services vs. Internal Resources

Some organizations run STR profiling internally; others outsource most or all authentication work. Neither choice is inherently "better." The decision is about resource allocation, documentation readiness, and how much operational variance your program can tolerate.

4.1 A make-vs-buy decision lens that procurement can defend

When you evaluate internal STR workflows versus a service partner, compare them as systems—not as single tests.

Consider documenting:

People: Who is trained to interpret electropherograms? What happens when a key analyst is out?
Process: How are deviations recorded? How are method changes documented over time?
Infrastructure: Who maintains instruments, ladders/controls, and software versions? How are updates governed?
Evidence: Can you produce a "publication-ready package" on demand, including raw traces, tables, and a signed interpretation?

If the internal path is chosen, use this article's evidence requests as a self-audit. If the outsourced path is chosen, require those same artifacts contractually.

Actionable checkpoint: Create a one-page internal vs. external evidence checklist and treat it as a gate before scaling projects or banking new cell lines.

4.2 Third-party verification and contamination troubleshooting

A practical reason teams outsource is the value of independent verification. A third-party report can reduce internal debate when results are unexpected—and it can support audits, partner communications, and publication packages.

Just as importantly, mature providers should have a clear pathway for investigating ambiguous profiles, suspected mixtures, or possible cross-contamination. If contamination risk is a recurring concern in your workflow, connect your vendor evaluation to a broader troubleshooting playbook. See Troubleshooting Cell Culture: Detecting Cross-Contamination and Drift for a deeper, operational view of how teams investigate these issues.

Actionable checkpoint: Ask the vendor to describe (in writing) how they handle suspected mixtures or cross-contamination signals—what repeat steps are available, and what additional evidence they provide.

Putting it together: an RFP-ready paragraph you can copy

Below is a vendor-neutral paragraph you can drop into an RFP or supplier questionnaire. It's designed to elicit auditable evidence rather than marketing claims:

"We are requesting STR profiling services for research use only. Please provide: (1) a one-page Quality Management System summary and evidence of controlled documentation and change management; (2) a redacted sample STR report and a complete file manifest (including allele tables and electropherograms), plus a plain-language description of your allele-calling review workflow; (3) a description of database comparison outputs and how ambiguous profiles (e.g., potential mixtures or degraded input) are handled; (4) sample acceptance criteria and chain-of-custody procedures; and (5) a security and data governance summary describing encrypted data transfer/storage, access controls/audit logging, and retention/deletion options. Where possible, include anonymized examples of how exceptions or re-runs are documented."

If you need the vendor's deliverables to map cleanly to manuscript or grant workflows, make that explicit. Many teams tie STR profiling outputs to general publication expectations for transparency and reproducibility. A deeper overview of those expectations is covered in NIH & Journal Requirements: Ensuring Your Cell Line Data Meets Industry Best Practices.

FAQs procurement teams ask before selecting an STR profiling service

Do we need raw electropherograms, or is a PDF summary enough?

For risk-managed programs, a signed PDF alone usually isn't sufficient. Electropherograms (or high-resolution trace outputs) and a machine-readable allele table make the result auditable, support internal QA review, and reduce rework if questions arise later.

What should we ask for if a profile looks "off" (possible mixture or unexpected match)?

Ask for the vendor's documented next-step policy: replicate PCR, re-extraction options, and how interpretation decisions are escalated for review. Request that any repeat work is traceable to the original accession and clearly documented in the final deliverable package.

How do we avoid over-promising internally on delivery timing?

Don't use turnaround time as a single-number KPI. Instead, evaluate whether the provider offers transparent scheduling, clear submission rules, and documented exception handling that makes timelines predictable across batches.

Can we keep parts of the workflow in-house?

Yes. Some teams run internal screening and outsource confirmatory testing (or vice versa). If you split the workflow, define file formats, naming conventions, and chain-of-custody responsibilities upfront so your audit trail doesn't break.

Conclusion: choose evidence, not promises

When you select an STR profiling partner, you're choosing the quality of your audit trail as much as the quality of your assay. Prioritize providers that can prove four things with real artifacts: a robust QMS, a publication-ready data package, stable operations at your scale, and security controls that protect your IP.

If you'd like to discuss how an STR profiling engagement can be structured to produce audit-friendly deliverables (RUO), you can review CD Genomics' Cell Line Identification and Authentication via STR Profiling scope and typical deliverables, or start a procurement workflow via Ordering.

Related Services

Author

Yang H. — Senior Scientist, CD Genomics; University of Florida.

Yang is a genomics researcher with over 10 years of research experience in genetics, molecular and cellular biology, sequencing workflows, and bioinformatic analysis. Skilled in both laboratory techniques and data interpretation, Yang supports RUO study design and NGS‑based projects.

References:

Science Journals — Editorial Policies: research materials transparency and reproducibility (accessed 2026).
International Cell Line Authentication Committee (ICLAC). Cell Line Checklist for Manuscripts and Grant Applications (03 Mar 2023); resource page.
ICLAC. Guide to Human Cell Line Authentication (2023); overview page.
ATCC. STR Profiling Analysis overview (accessed 2026); Interrogating the Database.
Labcorp. Human Cell Line Authentication Testing (accessed 2026); FAQs.
WiCell. Interpreting Your STR Results (accessed 2026).
NCBI Bookshelf — Authentication of Human and Mouse Cell Lines by STR (workflow and controls).
Tao R., Chen C., Sheng X., Xia R., Zhang X., Zhang J., et al. Validation of the Investigator 24plex QS Kit: a 6‑dye multiplex PCR assay for forensic application in the Chinese Han population. Forensic Sciences Research. 2019;5(1):33–40. doi:10.1080/20961790.2019.1665160. DOI link; PMC full text.
McDonald C., Taylor D., Linacre A. PCR in Forensic Science: A Critical Review. Genes. 2024;15(4):438. doi:10.3390/genes15040438. DOI link; PubMed.
U.S. National Institutes of Health (NIH). Using Genomic Data Responsibly (accessed 2026); Genomic Data User Code of Conduct.

For research purposes only, not intended for clinical diagnosis, treatment, or individual health assessments.